MELANOMA STAGE IV

This study is testing if a drug called infliximab is better than standard steroid treatment at resolving severe diarrhea and colon inflammation caused by immunotherapy drugs in people with advanced skin cancer. About 42 participants with stage III or IV skin cancer who develop th…

This study is testing whether adding one of two experimental cancer vaccines (SCIB1 or iSCIB1+) to standard immunotherapy drugs can improve outcomes for people with advanced, inoperable melanoma. The goal is to see if the vaccines help patients respond better to treatment and kee…

This study is testing whether adding a personalized cancer vaccine called EVX-01 to standard immunotherapy (pembrolizumab) can better control advanced melanoma. It involves 17 adults whose melanoma has spread or cannot be removed by surgery and who have not yet received this type…

This study is testing a new drug called ST101 for people with advanced solid tumors that have not responded to other treatments. The main goals are to find a safe dose and see if the drug can help control cancers like glioblastoma, melanoma, breast cancer, and prostate cancer. Th…

This early-stage study is testing whether delivering immunotherapy drugs directly into the spinal fluid, along with standard intravenous treatment, is safe and effective for patients with advanced lung cancer or melanoma that has spread to the lining of the brain. The trial invol…

This early-stage study is testing a new oral drug called SX-682 in people with advanced melanoma that has spread. The goal is to see if SX-682 can safely block certain cells that shield the tumor, allowing the patient's own immune system, boosted by an existing immunotherapy drug…

This study compares two immunotherapy approaches given before surgery for advanced melanoma that can still be removed. Patients receive either one immunotherapy drug or a combination of two drugs for 6 weeks before their operation, followed by additional treatment afterward. The …

This study observes melanoma survivors who have completed surgery and are receiving immunotherapy drugs to prevent cancer return. Researchers follow 126 patients for two years to track side effects, symptoms like fatigue and depression, and quality of life. The goal is to underst…